Term ends May 19, 2031 · Low confidence
20-year base term ends May 19, 2031
Held by Adverio Pharma GmbH
Filed Jul 2, 2020 as application 16/919,385 · Granted Sep 13, 2022
Base term, 20 years from filing
Today
2011
2031
Clock starts
May 19, 2011
May 19, 2011
Term ends
May 19, 2031
May 19, 2031
Granted
Sep 13, 2022
Sep 13, 2022
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,993,476, to May 19, 2031. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 19, 2011, when application 13/111,856, the earliest non-provisional in its chain, was filed (this one was filed Jul 2, 2020); a parent in its chain could not be resolved (the next row) | May 19, 2031 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,993,476) | resolves to May 19, 2031, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 15981598, 15348545, 14996678, 13851373 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | May 19, 2031 | Low confidence |
This family
| US 8,420,656 | In force May 2031 | May 2031 |
| US 8,921,377 | In force May 2031 | May 2031 |
| US 9,266,885 | In force May 2031 | May 2031 |
| Application 14/996,678 | Abandoned not computed | not computed |
| US 9,993,476 | In force May 2031 | May 2031 |
| US 10,736,896 | In force May 2031 | May 2031 |
| US 11,439,642 | this patent May 2031 | May 2031 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 4, 2021 Reel 55151, frame 491 | Follmann, Markus; Stasch, Johannes-peter; Redlich, Gorden; Ackerstaff, Jens; Griebenow, Nils; Kroh, Walter; Knorr, Andreas; Becker, Eva-maria; Wunder, Frank; Li, Volkhart Min-jian; Hartmann, Elke; Mittendorf, Joachim; Schlemmer, Karl-heinz; Jautelat, Rolf; Bierer, Donald | Bayer Schering Pharma Aktiengesellschaft | Assignment of Assignor's Interest |
| Feb 4, 2021 Reel 55152, frame 31 | Bayer Pharma Aktiengesellschaft | Bayer Intellectual Property GmbH | Nunc Pro Tunc Assignment |
| Feb 4, 2021 Reel 55152, frame 361 | Bayer Intellectual Property GmbH | Adverio Pharma GmbH | Nunc Pro Tunc Assignment |
| Feb 4, 2021 Reel 55222, frame 814 | Bayer Schering Pharma Aktiengesellschaft | Bayer Pharma Aktiengesellschaft | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
May 2031
Term ends May 19, 2031. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,993,476, ends no earlier than this term, so it caps nothing.
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.